P17.34 CONCURRENT CHEMORADIOTHERAPY IN GLIOBLASTOMA MULTIFORME: RETROSPECTIVE STUDY

BACKGROUND: Concurrent radiotherapy with Temozolomide (TMZ) is the standard of care in management of Glioblastoma Multiforme (GBM) since it led to survival benefit over radiotherapy alone. On the basis of this evidence, we initiated this study. The aim of this work was to investigate the efficacy and tolerability of radiotherapy plus TMZ in the treatment for newly diagnosed patients with GBM. METHODOLOGY: This is a retrospective descriptive study including newly diagnosed patients with GBM in clinical oncology department at Ain Shams University Hospitals during the period from January 2010 till December 2012. Eligible patients were treated with radiotherapy to a total dose of 60Gy/ 30 fractions/ 6 weeks concurrently with TMZ 75mg/m2 daily during the course of radiation followed by TMZ as adjuvant treatment for up to 6 cycles. RESULTS: During the period from January 2010 till December 2012, 57 GBM patients were enrolled in this retrospective study. The majority of the study group were males and constituted 77.2% (n = 44) while females constituted 22.8% (n = 13). The mean age was 52.2 years +/-10.2 SD and ranged from 28 to 74 years. Regarding performance status (PS) by SWOG classification 4 patients were classified as being PS 0, 49 patients were PS 1 and 4 patients were PS 2. Ten patients (17.5%) showed partial response (PR),24 patients (42.1%) showed stationary disease (SD), while 23 patients (40.4%) showed progressive disease (PD). The median progression free survival time was 8 months (95% CI 6.97-9.02months) and the median overall survival time was 16 months (95% CI 15.08-16.91 months). Regarding grade 3/4 treatment related toxicity during the entire study period (entire study period was defined as from study entry to 7 days after disease progression); there was no grade 3 or 4 hematological related toxicity. Grade 3/4 nausea and vomiting was observed in 5% (n = 3), fatigue in 10.5% (n = 6) and infection in 7% (n = 4) of study group CONCLUSION: Concurrent radiotherapy plus TMZ in the treatment of newly diagnosed GBM is effective and safe. Further larger prospective comparative studies are warranted to document this finding.